Dan has participated in drug development since 1994 as an executive in biotech/pharmaceutical companies, as a consultant and as a principal investigator. Most recently, Dan was the SVP of clinical development at Dermira where he led the development of monoclonal antibodies for psoriasis and atopic dermatitis. Previous executive roles include Gilead (vice president, clinical development), Trubion Pharmaceuticals (senior vice president and chief medical officer), Amgen (vice president, clinical development) and Immunex (vice president, clinical development).Additionally, Dan has provided clinical leadership as a consultant for many biotech/small pharmaceutical companies in multiple therapeutic areas, including rheumatology, neurology, and infectious diseases. Prior to joining industry in 1997, Dan was a practicing rheumatologist and a principal investigator in clinical studies.